Acetaminophen or NSAIDs for the treatment of osteoarthritis

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 1, 2006, Pages 117-129

  Bannwarth, Bernard ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Acetaminophen; Coxibs; Non steroidal anti inflammatory drugs; Osteoarthritis; Pain; Topical treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ANTIVITAMIN K; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIMETHYL SULFOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTACYCLIN; PROTON PUMP INHIBITOR; ROFECOXIB; SODIUM; THROMBOXANE A2; VALDECOXIB; WARFARIN;

ABDOMINAL PAIN; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ASTHMA; BLOOD TOXICITY; BURNING SENSATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL ADENOMA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; INJECTION SITE RASH; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY PERFUSION; KNEE OSTEOARTHRITIS; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG TOXICITY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PATIENT DECISION MAKING; PATIENT SATISFACTION; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSEUDOPORPHYRIA; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SKIN TOXICITY; SODIUM RETENTION; SYSTEMATIC REVIEW; THROMBOSIS; ULCER; URTICARIA; VOMITING;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 32544451770     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.09.004     Document Type: Review

References (57)

1. 1 American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update Arthritis and Rheumatism 43 2000 1905-1915
2. 2 K.M. Jordan N.K. Arden M. Doherty et. al. EULAR recommendations 2003: an evidenced based approach to the management of knee osteoarthritis: report of a Task Force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) Annals of the Rheumatic Diseases 62 2003 1145-1155
3. 3 W. Zhang M. Doherty N. Arden et. al. EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT) Annals of the Rheumatic Diseases 64 2005 669-681
4. 4 R.E. Say R. Thomson The importance of patient preferences in treatment decisions-challenges for doctors British Medical Journal 327 2003 542-545
5. 5 W. Zhang A. Jones M. Doherty Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: A meta-analysis of randomized controlled trials Annals of the Rheumatic Diseases 63 2004 901-907
6. 6 J.M. Bjordal A.E. Ljunggren A. Klovning S. Slordal Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: Meta-analysis of randomized placebo-controlled trials British Medical Journal 329 2004 1317-1320
7. 7 T. Pincus G. Koch H. Lei et. al. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): Two randomized, double blind, placebo-controlled, crossover clinical trials in patients with knee or hip osteoarthritis Annals of the Rheumatic Diseases 63 2004 931-939
8. 8 C. Miceli-Richard M. Le Bars N. Schmidely M. Dougados Paracetamol in osteoarthritis of the knee Annals of the Rheumatic Diseases 63 2004 923-930
9. 9 R. Neame W. Zhang M. Doherty A historic issue of the Annals: Three papers examine paracetamol in osteoarthritis Annals of the Rheumatic Diseases 63 2004 897-900
10. 10 G.G. Graham K.F. Scott Mechanisms of action of paracetamol and related analgesics Inflammopharmacology 11 2003 401-413
11. 2: Investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues The Journal of Pharmacology and Experimental Therapeutics 310 2004 642-647
12. 12 B. Bannwarth Gastrointestinal safety of paracetamol: Is there any cause for concern? Expert Opinion on Drug Safety 3 2004 269-272
13. 13 L.A. Garcia-Rodriguez S. Hernandez-Dias Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs Epidemiology 12 2001 570-576
14. 14 E. Rahme D. Pettitt J. LeLorier Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population Arthritis and Rheumatism 46 2002 3046-3054
15. 15 S.C. Lewis M.J. Langman J.R. Laporte et. al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious gastrointestinal bleeding: A meta-analysis based on individual patient data British Journal of Clinical Pharmacology 54 2002 320-326
16. 16 S.B. Abramson Et tu, acetaminophen? Arthritis and Rheumatism 46 2002 2831-2835
17. 17 G.G. Graham K.F. Scott R.O. Day Tolerability of paracetamol Drug Safety 28 2005 227-240
18. 18 J.J. Ofman C.H. Maclean W.L. Straus et. al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs The Journal of Rheumatology 29 2002 804-812
19. 19 L. Laine Gastrointestinal effects of NSAIDs and coxibs Journal of Pain and Symptom Management 25 supplement 2003 S32-S40
20. 20 M.A. Perazella COX-2 selective inhibitors: Analysis of the renal effect Expert Opinion on Drug Safety 1 2002 53-64
21. 21 M.L. Bouvy E.R. Heerdink A.W. Hoes H.G.M. Leufkens Effects of NSAIDs on the incidence of hospitalisation for renal dysfunction in users of ACE inhibitors Drug Safety 26 2003 983-989
22. 22 T.J. Aw S.J. Haas D. Liew H. Krum Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Archives of Internal Medicine 165 2005 490-496
23. 23 B. Bannwarth Do selective cyclo-oxygenase-2 inhibitors have a future? Drug Safety 28 2005 183-189
24. 24 G. Singh J.D. Miller D.M. Huse et. al. Consequences of increased systolic pressure in patients with osteoarthritis and rheumatoid arthritis The Journal of Rheumatology 30 2003 714-719
25. 25 B.M. Egan Nonnarcotic analgesic use and the risk of hypertension in US women Hypertension 4 2002 601-603
26. 26 G.C. Curhan W.C. Willet B. Rosner M.J. Stampfer Frequency of analgesic use and risk of hypertension in younger women Archives of Internal Medicine 162 2002 2204-2208
27. 27 J. Dedier M.J. Stampfer S.E. Hankinson et. al. Nonnarcotic analgesic use and the risk of hypertension in US women Hypertension 40 2002 604-608
28. 28 T.V. Perneger P.K. Whelton M.J. Klag Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs The New England Journal of Medicine 331 1994 1675-1679
29. 29 M. Segasothy G.L. Chin K.K. Sia et. al. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis British Journal of Rheumatology 34 1995 162-165
30. 30 P. Courtney M. Doherty Key questions concerning paracetamol and NSAIDs for osteoarthritis Annals of the Rheumatic Diseases 61 2002 767-773
31. 31 B. Bannwarth F. Péhourcq Pharmacological rationale for the clinical use of paracetamol: Pharmacokinetic and pharmacodynamic issues Drugs 63 2 2003 5-13
32. 32 C.K. Svensson E.W. Cowen A.A. Gaspari Cutaneous drug reactions Pharmacological Reviews 53 2001 357-379
33. 33 C. Jenkins J. Costello L. Hodge Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice British Medical Journal 328 2004 434-437
34. 34 G. Senna M.B. Bilo L. Antonicelli et. al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients Allergie et Immunologie (Paris) 36 2004 215-218
35. 35 M. Sanchez-Borges F. Caballero-Fonseca A. Capriles-Hulett Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase-2 inhibitors rofecoxib and valdecoxib Annals of Allergy Asthma and Immunology 94 2005 34-38
36. 36 J.H. Rubenstein L. Laine Systematic review: The hepatotoxicity of non-steroidal anti-inflammatory drugs Alimentary Pharmacology and Therapeutics 20 2004 373-380
37. 37 A. Wegman D. Van der Windt M. Van Tulder et. al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines The Journal of Rheumatology 31 2004 344-354
38. 38 T. Pincus G.G. Koch T. Sokka et. al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee Arthritis and Rheumatism 44 2001 1587-1598
39. 39 L. Fraenkel S.T. Bogardus Jr J. Concato D.R. Wittink Treatment options in knee osteoarthritis. The patient's perspective Archives of Internal Medicine 164 2004 1299-1304
40. 40 F. Wolfe S. Zhao N. Lane Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia Arthritis and Rheumatism 43 2000 378-385
41. 41 T. Pincus C. Swearingen P. Cummings L.F. Callahan Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis The Journal of Rheumatology 27 2000 1020-1027
42. 42 D.L. Scott G. Kingsley Translating research into practice: acetaminophen in osteoarthritis revisited The Journal of Rheumatology 30 2003 199-202
43. 43 L. March L. Irwig J. Schwarz et. al. n Of 1 trials comparing non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis British Medical Journal 309 1994 1041-1045
44. 44 A.C.M. Wegman D.A.W.M. Van der Windt M. de Haan et. al. Switching from NSAIDs to paracetamol: A series of n of 1 trials for individual patients with osteoarthritis Annals of the Rheumatic Diseases 62 2003 1156-1161
45. 45 M.C. Hochberg What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective Clinical and Experimental Rheumatology 19 supplement 25 2001 S15-S22
46. 46 T.J. Schnitzer G.R. Burmester E. Mysler et. al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: Randomized controlled trial Lancet 364 2004 665-674
47. 47 A. Mahajan A. Sharma COX-2 selective nonsteroidal anti-inflammatory drugs: Current status The Journal of the Association of Physicians of India 53 2005 200-204
48. 48 F.K.L. Chan L.C.T. Hung B.Y. Suen et. al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patient with arthritis The New England Journal of Medicine 347 2002 2104-2110
49. 49 B.M.R. Spiegel C.F. Chiou J.J. Ofman Minimizing complications from nonsteroidal anti-inflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups Arthritis and Rheumatism 53 2005 185-197
50. 50 D.W.J. Clark D. Layton S.A.W. Shakir Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology Drug Safety 27 2004 427-456
51. 51 J. Lenzer FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke British Medical Journal 330 2005 440
52. 52 S.P. Johnsen H. Larsson R.E. Tarone et. al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs Archives of Internal Medicine 165 2005 978-984
53. 53 C.A. Heyneman C. Lawless-Liday G.C. Wall Oral versus topical NSAIDs in rheumatic diseases. A comparison Drugs 60 2000 555-574
54. 54 J. Lin W. Zhang A. Jones M. Doherty Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials British Medical Journal 329 2004 324-326
55. 55 C. Cooper Topical NSAIDs in osteoartritis. Best used for short periods during flare-ups in the disease British Medical Journal 329 2004 304-305
56. 56 S.H. Roth J.Z. Shainhouse Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee. A randomized, double-blind, vehicle-controlled clinical trial Archives of Internal Medicine 164 2004 2017-2023
57. 57 H. Bagheri V. Lhiaubet J.L. Montastruc N. Chouini-Lalanne Phorosensitivity to ketoprofen. Mechanisms and pharmacoepidemiological data Drug Safety 22 2000 339-349